Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety

Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety

Background/AimsThe treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection. We investigated the real-world efficacy, changes in liver stiffness and noninvasive fibrosis markers, and the safety of...

Full description

Bibliographic Details
Main Authors: Hye Won Lee, Se Rim Oh, Dong Yun Kim, Yechan Jeong, Seungtaek Kim, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park
Format: Article
Language:English
Published: Gastroenterology Council for Gut and Liver 2018-05-01
Series:Gut and Liver
Subjects:
daclatasvir
asunaprevir
hepatitis c
genotype 1b
fibrosis
Online Access:http://gutnliver.org/journal/view.html?doi=10.5009/gnl17298

Internet

http://gutnliver.org/journal/view.html?doi=10.5009/gnl17298

Similar Items